Preparation and in vivo study of dry powder microspheres for nasal immunization

Journal of Drug Targeting

Volumn 18, Issue 3, 2010, Pages 235-242

  Tafaghodi, Mohsen ^a,b   Rastegar, Somayeh ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Alginate microspheres; Cross linked dextran microspheres; Nasal immunization; Quillaja saponins; Tetanus toxoid

Indexed keywords

ALGINIC ACID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICROSPHERE; SAPONIN; SEPHADEX; TETANUS TOXIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SYNTHESIS; DRY POWDER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; IN VIVO STUDY; MICROEMULSION; MICROENCAPSULATION; MOLECULAR SIZE; NONHUMAN; NOSE MUCUS; PRIORITY JOURNAL; QUILLAJA; RABBIT;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ALGINATES; ANIMALS; CROSS-LINKING REAGENTS; DEXTRANS; DRUG CARRIERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXCIPIENTS; FEMALE; GLUCURONIC ACID; HEXURONIC ACIDS; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; MICROSPHERES; PARTICLE SIZE; QUILLAJA; RABBITS; SAPONINS; TETANUS TOXOID; VACCINES;

EID: 77949415982     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611860903434035     Document Type: Article

References (50)

1. Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. (2005). Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev, 57: 411-430.
2. Amin M, Jaafari MR, Tafaghodi M. (2009). Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits. Colloids Surf B Biointerfaces, 74: 225-229.
3. Bacon A, Makin J, Sizer PJ, Jabbal-Gill I, Hinchcliffe M, Illum L, Chatfield S, Roberts M. (2000). Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun, 68: 5764-5770.
4. Bjork E, Edman P. (1990). Characterization of degradable starch microspheres as a nasal delivery system for drugs. Int J Pharm, 62(2-3): 187-192.
5. Carr RM, Lolachi CM, Albaran RG, Ridley DM, Montgomery PC, O'Sullivan NL. (1996). Nasal-associated lymphoid tissue is an inductive site for rat tear IgA antibody responses. Immunol Invest, 25: 387-396.
6. Chandler SG, Ilium L, Thomas NW. (1991). Nasal absorption in rats. II. Effect of enhancers on insulin absorption and nasal histology. Int J Pharm, 76(1-2): 61-70.
7. Cornaz A-L, De Ascentis A, Colombo P, Buri P. (1996). In vitro characteristics of nicotine microspheres for transnasal delivery. Int J Pharm, 129(1-2): 175-183.
8. Csaba N, Garcia-Fuentes M, Alonso MJ. (2009). Nanoparticles for nasal vaccination. Adv Drug Deliv Rev, 61: 140-157.
9. Ellis JA, West KH, Waldner C, Rhodes C. (2005). Efficacy of a saponin-adjuvanted inactivated respiratory syncytial virus vaccine in calves. Can Vet J, 46: 155-162.
10. Eyles JE, Williamson ED, Alpar HO. (1999). Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volume. Int J Pharm, 189: 75-79.
11. Garmise RJ, Staats HF, Hickey AJ. (2007). Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. AAPS PharmSciTech, 8: E81.
12. Gill IJ, Fisher AN, Farraj N, Pitt CG, Davis SS, Illum L. (1998). Intranasal absorption of granulocyte-colony stimulating factor (G-CSF) from powder formulations, in sheep. Eur J Pharm Sci, 6: 1-10.
13. Gupta RK, Siber GR. (1995). Adjuvants for human vaccines-current status, problems and future prospects. Vaccine, 13: 1263-1276.
14. Hagenaars N, Verheul RJ, Mooren I, de Jong PH, Mastrobattista E, Glansbeek HL, Heldens JG, van den Bosch H, Hennink WE, Jiskoot W. (2009). Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine. J Control Release: 140(2):126-133.
15. Illum L, Jørgensen H, Bisgaard H, Krogsgaard O, Rossing N. (1998). Bioadhesive microspheres as a potential nasal drug delivery system. Int J Pharm, 39(3): 189-199.
16. Illum L, Fisher AN, Jabbal-Gill I, Davis SS. (2001). Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. Int J Pharm, 222: 109-119.
17. Illum L, Farraj NF, Davis SS, Johansen BR, O'Hagan DT. (1990). Investigation of the nasal absorption of biosynthetic human growth hormone in sheep-use of a bioadhesive microsphere delivery system. Int J Pharm, 63(3): 207-211.
18. Ishii M, Kojima N. (2009). Mucosal adjuvant activity of oligomannosecoated liposomes for nasal immunization. Glycoconj J. DOI 10.1007/s10719-009-9263-8.
19. Jain AK, Khar RK, Ahmed FJ, Diwan PV. (2008). Effective insulin delivery using starch nanoparticles as a potential trans-nasal mucoadhesive carrier. Eur J Pharm Biopharm, 69: 426-435.
20. Jiang HL, Kang ML, Quan JS, Kang SG, Akaike T, Yoo HS, Cho CS. (2008). The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization. Biomaterials, 29: 1931-1939.
21. Johansen P, Men Y, Merkle HP, Gander B. (2000). Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm, 50: 129-146.
22. Kayamuro H, Abe Y, Yoshioka Y, Katayama K, Nomura T, Yoshida T, Yamashita K, Yoshikawa T, Kawai Y, Mayumi T, Hiroi T, Itoh N, Nagano K, Kamada H, Tsunoda S, Tsutsumi Y. (2009). The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses. Biomaterials, 30: 5869-5876.
23. Kensil CR, Wu JY, Soltysik S. (1995). Structural and immunological characterization of the vaccine adjuvant QS-21. Pharm Biotechnol, 6: 525-541.
24. Kensil CR. (1996). Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst, 13: 1-55.
25. Lemoine D, Wauters F, Bouchend'homme S, Préat V. (1998). Preparation and characterization of alginate microspheres containing a model antigen. Int J Pharm, 176(1): 9-19.
26. Makidon PE, Nigavekar SS, Bielinska AU, Mank N, Shetty AM, Suman J, Knowlton J, Myc A, Rook T, Baker JR. (2009). Characterization of stability and nasal delivery systems for immunization with nanoemulsion-based vaccines. J Aerosol Med Pulm Drug Deliv.
27. Nishino M, Mizuno D, Kimoto T, Shinahara W, Fukuta A, Takei T, Sumida K, Kitamura S, Shiota H, Kido H. (2009). Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigs. Vaccine, 27: 5620-5627.
28. O'agan DT. (1996). The intestinal uptake of particles and the implications for drug and antigen delivery. J Anat, 189 (Pt 3): 477-482.
29. O'Hagan DT, Rafferty D, Wharton S, Illum L. (1993). Intravaginal immunization in sheep using a bioadhesive microsphere antigen delivery system. Vaccine, 11: 660-664.
30. Oechslein CR, Fricker G, Kissel T. (1996). Nasal delivery of octreotide: Absorption enhancement by particulate carrier systems. Int J Pharm, 139(1-2): 25-32.
31. Payne JM, Sansom BF, Garner RJ, Thomson AR, Miles BJ. (1960). Uptake of small resin particles (1-5 microns diameter) by the alimentary canal of the calf. Nature, 188: 586-587.
32. Pereswetoff-Morath L. (1998). Microspheres as nasal drug delivery systems. Adv Drug Deliv Rev, 29: 185-194.
33. Pereswetoff-Morath L, Edman P. (1995). Dextran microspheres as a potential nasal drug delivery system for insulin-in vitro and in vivo properties. Int J Pharm, 124(1): 37-44.
34. Pereswetoff-Morath L, Edman P. (1996). Immunological consequences of nasal drug delivery in dextran microspheres and ethyl(hydroxyethyl)cellulose in rats. Int J Pharm, 128(1-2): 23-28.
35. Pickering RJ, Smith SD, Strugnell RA, Wesselingh SL, Webster DE. (2006). Crude saponins improve the immune response to an oral plant-made measles vaccine. Vaccine, 24: 144-150.
36. Rebelatto MC, Guimond P, Bowersock TL, HogenEsch H. (2001). Induction of systemic and mucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles. Vet Immunol Immunopathol, 83: 93-105.
37. Rydell N, Sjöholm I. (2004). Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant. Vaccine, 22: 1265-1274.
38. Rydell N, Sjöholm I. (2005). Mucosal vaccination against diphtheria using starch microparticles as adjuvant for cross-reacting material (CRM197) of diphtheria toxin. Vaccine, 23: 2775-2783.
39. Ryden L, Edman P. (1982). Effect of polymers and microspheres on the nasal absorption of insulin in rats. Int J Pharm, 83(1-3): 1-10.
40. Sajadi Tabassi SA, Tafaghodi M, Jaafari MR. (2008). Induction of high antitoxin titers against tetanus toxoid in rabbits by intranasal immunization with dextran microspheres. Int J Pharm, 360: 12-17.
41. Sanders MT, Deliyannis G, Pearse MJ, McNamara MK, Brown LE. (2009). Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract. Vaccine, 27: 2475-2482.
42. Skene CD, Sutton P. (2006). Saponin-adjuvanted particulate vaccines for clinical use. Methods, 40: 53-59.
43. Song X, Hu S. (2009). Adjuvant activities of saponins from traditional Chinese medicinal herbs. Vaccine, 27: 4883-4890.
44. Stertman L, Lundgren E, Sjöholm I. (2006). Starch microparticles as a vaccine adjuvant: only uptake in Peyer's patches decides the profile of the immune response. Vaccine, 24: 3661-3668.
45. Stertman L, Strindelius L, Sjöholm I. (2004). Starch microparticles as an adjuvant in immunisation: effect of route of administration on the immune response in mice. Vaccine, 22: 2863-2872.
46. Sun HX, Xie Y, Ye YP. (2009). Advances in saponin-based adjuvants. Vaccine, 27: 1787-1796.
47. Tafaghodi M, Abolghasem Sajadi Tabassi S, Jaafari MR, Zakavi SR, Momen-Nejad M. (2004). Evaluation of the clearance characteristics of various microspheres in the human nose by gammascintigraphy. Int J Pharm, 280: 125-135.
48. Tafaghodi M, Jaafari MR, Sajadi Tabassi SA. (2006). Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN. Eur J Pharm Biopharm, 64: 138-145.
49. Tafaghodi M, Sajadi Tabassi SA, Jaafari MR. (2006). Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. Int J Pharm, 319: 37-43.
50. Ugwoke MI, Agu RU, Verbeke N, Kinget R. (2005). Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev, 57: 1640-1665.